Technology Bundle ID: TAB-3414

Codon-Optimized Gene Therapy for Niemann-Pick Disease Type C

Request More Info
Licensing Contact:
Primary Inventors: 
Charles Venditti (NHGRI), William Pavan (NHGRI)
Co-Inventors: 
Randy Chandler (NHGRI)
Institute or Center: 
NHGRI

Niemann Pick Disease Type C (NPC) is a rare and fatal, autosomal recessive, neurodegenerative disease that can present in infants, children, or adults. Most patients with NPC have mutations in NPC1, a gene implicated in intracellular cholesterol trafficking, which results in intracellular accumulation of unesterified cholesterol in late edosomal/lysosomal structures and of glycosphingolipids, especially in neuronal tissue. No curative therapy exists at present.

Adding to their previous work and patent portfolio of NPC gene constructs, NHGRI investigators have generated improved and codon-optimized gene vectors. These new adeno-associated viral (AAV) vectors have been shown to clear or significantly remove accumulated cellular cholesterol in human mutant NPC1 cell models. In addition to codon-optimization, the vectors can include various tags (e.g., a protein transduction domain peptide, which allows for trans-cellular correction of cells that have not been infected with therapy vector), specialized promoter to increase expression, strong translation initiation site, and/or multiple stop signals.

Applications:

These improved vector constructs may be utilized for gene therapy of NPC and serve as a model vector for other cholesterol storage disease or disorders.

Advantages:

Codon-optimization of the sequence and specialized tags.

Patents

PCT Application PCT/US2018/038584
Filed on 2018-06-20
US Application 16/623,863
Filed on 2019-12-18
US Application 62/522,677
Filed on 2017-06-20

Also entered national phases in Europe and Canada

For E-185-2014 also entered national phases in Europe (allowed) and Canada

Updated

May 29, 2020

Data Source: 
tts